Can dd-cfDNA Transform Rejection Surveillance? | A webinar presented by Natera
Next month, a one-hour webinar will bring together leading transplant experts to unveil the latest findings from the DEFINE-HT study and explore the clinical utility of donor-derived cell-free DNA (dd-cfDNA) with Donor Quantity Score (DQS) in heart transplantation.
This webinar will highlight how these innovations improve detection of rejection, reduce reliance on invasive biopsies, and pave the way for more personalized patient management.
Attendees will gain first-hand insights into how dd-cfDNA testing—enhanced by a two-threshold approach—outperforms traditional surveillance, reduces false positives, and enables earlier, more accurate interventions to protect graft health and improve outcomes.
DEFINE-HT Study Initial Results
- First multicenter, longitudinal study linking dd-cfDNA to clinical outcomes in heart transplantation
- Elevated dd-cfDNA percentage and DQS associated with an increased risk of poor one-year outcomes
The Two-Threshold Algorithm: Fraction + DQS
- How integrating dd-cfDNA fraction (%) and quantity (DQS) improves sensitivity and specificity
- Real-World Clinical Application—Case studies where dd-cfDNA with DQS changed patient management
SPEAKERS:
Palak Shah, MD, MS, FACC, FHFSA, FAHA
Shelley Hall, MD, FACC, FHFSA, FAST